Free Trial

Vaxcyte (PCVX) Competitors

Vaxcyte logo
$33.27 +0.33 (+1.00%)
Closing price 04:00 PM Eastern
Extended Trading
$33.53 +0.26 (+0.78%)
As of 06:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PCVX vs. SMMT, ITCI, GMAB, RDY, ASND, VTRS, QGEN, MRNA, BPMC, and BBIO

Should you be buying Vaxcyte stock or one of its competitors? The main competitors of Vaxcyte include Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Qiagen (QGEN), Moderna (MRNA), Blueprint Medicines (BPMC), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry.

Vaxcyte vs. Its Competitors

Vaxcyte (NASDAQ:PCVX) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Vaxcyte presently has a consensus target price of $136.50, suggesting a potential upside of 310.28%. Summit Therapeutics has a consensus target price of $34.67, suggesting a potential upside of 53.26%. Given Vaxcyte's stronger consensus rating and higher possible upside, equities analysts plainly believe Vaxcyte is more favorable than Summit Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vaxcyte
0 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
3.10
Summit Therapeutics
2 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.79

Summit Therapeutics has higher revenue and earnings than Vaxcyte. Summit Therapeutics is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VaxcyteN/AN/A-$463.93M-$3.99-8.34
Summit Therapeutics$700K23,998.85-$221.32M-$0.34-66.53

Vaxcyte has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -1.01, indicating that its share price is 201% less volatile than the S&P 500.

Vaxcyte's return on equity of -17.12% beat Summit Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
VaxcyteN/A -17.12% -16.26%
Summit Therapeutics N/A -62.87%-51.61%

In the previous week, Summit Therapeutics had 11 more articles in the media than Vaxcyte. MarketBeat recorded 14 mentions for Summit Therapeutics and 3 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 1.12 beat Summit Therapeutics' score of 0.62 indicating that Vaxcyte is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vaxcyte
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Summit Therapeutics
3 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

96.8% of Vaxcyte shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 3.1% of Vaxcyte shares are owned by company insiders. Comparatively, 84.9% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Vaxcyte beats Summit Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Vaxcyte News Delivered to You Automatically

Sign up to receive the latest news and ratings for PCVX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PCVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PCVX vs. The Competition

MetricVaxcyteMED IndustryMedical SectorNASDAQ Exchange
Market Cap$4.25B$2.88B$5.54B$8.87B
Dividend YieldN/A2.64%5.39%4.10%
P/E Ratio-8.3421.3126.1719.90
Price / SalesN/A278.47414.67113.66
Price / CashN/A41.4736.1356.90
Price / Book1.257.518.055.38
Net Income-$463.93M-$55.05M$3.15B$248.50M
7 Day Performance0.54%2.45%1.85%2.97%
1 Month Performance-5.00%7.33%4.81%6.02%
1 Year Performance-56.26%5.38%34.86%20.39%

Vaxcyte Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PCVX
Vaxcyte
1.7866 of 5 stars
$33.27
+1.0%
$136.50
+310.3%
-57.2%$4.25BN/A-8.34160News Coverage
Positive News
SMMT
Summit Therapeutics
2.6356 of 5 stars
$20.39
-0.8%
$35.09
+72.1%
+160.4%$15.14B$700K-59.97110Analyst Upgrade
ITCI
Intra-Cellular Therapies
0.908 of 5 stars
$131.87
flat
$109.70
-16.8%
N/A$14.05B$680.50M-151.57560
GMAB
Genmab A/S
3.8891 of 5 stars
$20.68
-2.3%
$39.17
+89.4%
-16.5%$13.26B$3.12B11.752,682High Trading Volume
RDY
Dr. Reddy's Laboratories
2.8098 of 5 stars
$15.31
+0.5%
$16.95
+10.7%
-1.0%$12.78B$3.81B23.2027,811
ASND
Ascendis Pharma A/S
3.5662 of 5 stars
$175.78
-0.6%
$220.67
+25.5%
+28.4%$10.75B$393.54M-27.991,017Positive News
VTRS
Viatris
3.0472 of 5 stars
$8.85
-0.2%
$10.40
+17.5%
-13.3%$10.39B$14.74B-2.7932,000
QGEN
Qiagen
4.2068 of 5 stars
$46.72
-0.1%
$47.74
+2.2%
+23.2%$10.39B$2.00B117.145,765Dividend Announcement
MRNA
Moderna
4.3608 of 5 stars
$25.67
-0.9%
$46.61
+81.6%
-75.3%$9.93B$3.14B-2.945,800Trending News
Options Volume
BPMC
Blueprint Medicines
1.5462 of 5 stars
$128.40
+0.2%
$128.06
-0.3%
+17.5%$8.29B$508.82M-51.98640High Trading Volume
BBIO
BridgeBio Pharma
4.7139 of 5 stars
$42.17
+1.1%
$56.67
+34.4%
+69.8%$8.01B$127.42M-11.95400Analyst Forecast
Insider Trade

Related Companies and Tools


This page (NASDAQ:PCVX) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners